A detailed history of Csenge Advisory Group transactions in Novo Nordisk A S stock. As of the latest transaction made, Csenge Advisory Group holds 23,268 shares of NVO stock, worth $3.32 Million. This represents 0.17% of its overall portfolio holdings.

Number of Shares
23,268
Previous 19,574 18.87%
Holding current value
$3.32 Million
Previous $2.02 Million 47.58%
% of portfolio
0.17%
Previous 0.13%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 03, 2024

BUY
$102.11 - $135.92 $377,194 - $502,088
3,694 Added 18.87%
23,268 $2.99 Million
Q4 2023

Feb 13, 2024

BUY
$87.78 - $105.45 $861,736 - $1.04 Million
9,817 Added 100.61%
19,574 $2.02 Million
Q3 2023

Nov 01, 2023

BUY
$90.94 - $199.54 $587,290 - $1.29 Million
6,458 Added 195.76%
9,757 $887,000
Q2 2023

Jul 20, 2023

BUY
$155.98 - $172.65 $192,011 - $212,532
1,231 Added 59.53%
3,299 $533,000
Q1 2023

May 01, 2023

SELL
$132.34 - $159.14 $21,306 - $25,621
-161 Reduced 7.22%
2,068 $329,000
Q4 2022

Feb 10, 2023

SELL
$102.55 - $135.33 $32,098 - $42,358
-313 Reduced 12.31%
2,229 $301,000
Q3 2022

Oct 04, 2022

BUY
$95.28 - $116.93 $9,051 - $11,108
95 Added 3.88%
2,542 $253,000
Q2 2022

Jul 27, 2022

SELL
$103.24 - $121.81 $1,961 - $2,314
-19 Reduced 0.77%
2,447 $273,000
Q1 2022

May 09, 2022

BUY
$93.1 - $112.54 $5,492 - $6,639
59 Added 2.45%
2,466 $274,000
Q4 2021

Feb 10, 2022

SELL
$95.88 - $117.08 $15,628 - $19,084
-163 Reduced 6.34%
2,407 $203,000
Q3 2021

Oct 20, 2021

BUY
$84.42 - $106.62 $13,760 - $17,379
163 Added 6.77%
2,570 $246,000
Q2 2021

Jul 21, 2021

BUY
$67.66 - $84.76 $162,857 - $204,017
2,407 New
2,407 $203,000
Q4 2018

Feb 07, 2019

SELL
$41.54 - $47.25 $1,786 - $2,031
-43 Closed
0 $0
Q3 2018

Nov 19, 2018

BUY
$46.76 - $51.24 $2,010 - $2,203
43 New
43 $1,000

Others Institutions Holding NVO

About NOVO NORDISK A S


  • Ticker NVO
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 2,257,289,984
  • Market Cap $322B
  • Description
  • Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabeti...
More about NVO
Track This Portfolio

Track Csenge Advisory Group Portfolio

Follow Csenge Advisory Group and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Csenge Advisory Group, based on Form 13F filings with the SEC.

News

Stay updated on Csenge Advisory Group with notifications on news.